<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499265</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000553460</org_study_id>
    <secondary_id>WILEX-WX-60-004</secondary_id>
    <nct_id>NCT00499265</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      WX-671 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
      growth. Giving gemcitabine together with WX-671 may kill more tumor cells.

      PURPOSE: This randomized phase II trial is studying how well gemcitabine works when given
      together with WX-671 or when given alone in treating patients with locally advanced
      pancreatic cancer that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the antitumor activity of two different doses of anti-uPA serine protease
           inhibitor WX-671 when given in combination with gemcitabine hydrochloride in patients
           with locally advanced unresectable pancreatic cancer.

        -  Compare the efficacy, in terms of response rate, progression-free survival, time to
           first metastasis, overall survival, and tumor and uPA system-related markers, of these
           regimens in these patients.

        -  Compare the safety, in terms of vital signs, ECG, biochemistry, hematology (including
           coagulation), and adverse events, of these regimens.

      OUTLINE: This is an open-label, randomized, multicenter study. Patients are randomized to 1
      of 3 treatment arms.

        -  Arm I: Patients receive of oral anti-uPA serine protease inhibitor WX-671 once daily in
           weeks 1-8 (weeks 1-4 of each subsequent course) and gemcitabine hydrochloride IV over 30
           minutes once weekly in weeks 1-7 (weeks 1-3 of each subsequent course) of course 1. All
           subsequent courses repeat every 4 weeks in the absence of disease progression or
           unacceptable toxicity.

        -  Arm II: Patients receive oral anti-uPA serine protease inhibitor WX-671 (at a lower dose
           than in arm I) once daily in weeks 1-8 (weeks 1-4 of each subsequent course) and
           gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 1-7 (weeks 1-3 of each
           subsequent course) of course 1. All subsequent courses repeat every 4 weeks in the
           absence of disease progression or unacceptable toxicity.

        -  Arm III: Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly in
           weeks 1-7 (weeks 1-3 of each subsequent course) of course 1. All subsequent courses
           repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine plus 200 mg WX-671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine plus 400 mg WX-671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serine Proteinase Inhibitor WX-671</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Gemcitabine plus 200 mg WX-671</arm_group_label>
    <other_name>MESUPRON</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serine Proteinase Inhibitor WX-671</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Gemcitabine plus 400 mg WX-671</arm_group_label>
    <other_name>MESUPRON</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Inclusion criteria:

               -  Locally advanced, unresectable, non-metastatic, histologically proven pancreatic
                  adenocarcinoma (lymph nodes will not be considered metastases)

          -  Exclusion criteria:

               -  Any distant metastases

        PATIENT CHARACTERISTICS:

          -  Inclusion criteria:

               -  ECOG performance status ≤ 1

               -  Life expectancy &gt; 12 weeks

               -  Normal 12-lead ECG or only clinically insignificant abnormalities in the judgment
                  of the investigator

               -  Female patients of child-bearing potential will be required to use an effective
                  method of birth control for the duration of the study to prevent pregnancy

               -  ANC ≥ 1,500/mm³

               -  Platelet count ≥ 100,000/mm³

               -  Hemoglobin ≥ 9 g/dL

               -  Total bilirubin ≤ 1.5 times ULN

               -  AST and ALT ≤ 2.5 times ULN

               -  Alkaline phosphatase ≤ 2.5 times ULN

               -  Creatinine ≤ 2 times ULN or creatinine clearance &gt; 45 mL/min

          -  Exclusion criteria:

               -  History of or current primary blood coagulation or bleeding disorders such as
                  hemophilia

               -  Any unrelated illness, e.g., active infection, inflammation, medical condition or
                  laboratory abnormalities, which in the judgment of the investigator might
                  significantly affect the patient's study participation

               -  Any surgical or medical condition that might significantly alter the absorption,
                  distribution, metabolism or excretion of any drug

               -  Significant cardiac insufficiency (NYHA classification III or IV), presence of
                  unstable angina or myocardial infarction within the previous 6 months, use of
                  ongoing maintenance therapy for life threatening arrhythmia or known pulmonary
                  hypertension

               -  Any secondary malignancies within the last 5 years except for surgically cured
                  non-melanoma skin cancer or cervical carcinoma in situ

               -  Pregnancy (positive serum pregnancy test) or lactation

               -  Known hepatitis B/C or HIV infection

               -  Known hypersensitivity to any of the components in the anti-uPA serine protease
                  inhibitor WX-671 capsules or gemcitabine hydrochloride infusion or other medical
                  reasons for not being able to receive adequate pre-medication (for example,
                  antihistamine or anti-inflammatory agents)

        PRIOR CONCURRENT THERAPY:

          -  Permitted:

               -  Growth factors for treatment (not prophylaxis, i.e., epoetin alfa), analgesics,
                  blood transfusions, antibiotics, bisphosphonates, other hormonal therapy for
                  contraceptive practice, replacement therapy such as thyroid replacement or
                  adrenal insufficiency as appropriate and medications for acute or chronic
                  conditions not listed under the exclusion criteria

               -  Embolization (i.e. for hematuria)

               -  Subjects can receive blood transfusions as medically appropriate during the study

                    -  Subjects who require a blood transfusion during screening must have stable
                       hemoglobin (≥9.0 g/dL [5.6 mmol/L]) without the need for further
                       transfusions within 2 weeks before the first dose of anti-uPA serine
                       protease inhibitor WX-671 to remain eligible

               -  Prophylactic use of growth factors to support neutrophils

          -  Prohibited:

               -  Anticoagulant or thrombolytic therapy within four weeks prior to start of
                  treatment (except low dose anticoagulant therapy with unfractionated heparin ≤
                  15000 IU/d, low molecular weight heparin ≤ 5000 IE anti-Xa activity or acetyl
                  salicylic acid ≤ 100 mg/d at the discretion of the investigator)

               -  Anticancer therapies such as biologic therapy and chemotherapy (other than study
                  drugs)

               -  Radiation therapy (during the treatment phase of the protocol; increased bone
                  pain not controlled by medication and requiring palliative therapy will be
                  considered disease progression)

               -  Laser treatment

               -  Any other investigational agent

               -  Thalidomide

               -  Immunosuppressive therapies (inhaled or replacement dose corticosteroids are
                  permitted).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carola Mala, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wilex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Meyerhof-Zentrum Tagesklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Muenchen Bogenhausen</name>
      <address>
        <city>Munich</city>
        <zip>D-81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Onkologiai Tanzek</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar County Hospital</name>
      <address>
        <city>Gydr</city>
        <zip>h-9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs Faculty of Medicine</name>
      <address>
        <city>Pecs</city>
        <zip>H-7643</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged University</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Livorno</name>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori/Fondazione Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Filippo Neri</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altai Oncology Center</name>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oncology Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>109033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Research Institute of Oncology - Omsk</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico M.D. Anderson International Espana</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Center</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bukovinian State Medical University</name>
      <address>
        <city>Chernivtsy</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk State Medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankovsk Regional Oncology Center</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grigoriev Institute for Radiology Academy of Medical Science of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Kiev</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Medical Stomatological Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Serine Proteinase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

